Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

1
Player Avatar NHWeston102 (75.22) Submitted: 8/6/2012 8:26:22 PM : Outperform Start Price: $4.85 EXEL Score: -24.20

Buying opportunity!!

Featured Broker Partners


Advertisement